Pharmaceuticals & Life Sciences

Product Design for Pharmaceuticals & Life Sciences

Product Design for pharmaceuticals & life sciences, built around the constraint that defines the sector: GxP validation means every system change needs documented evidence before it reaches production.

Regulations in scope
5
Systems we integrate
5
Typical first release
6 weeks

What changes when it is pharmaceuticals & life sciences

Most products fail by building the wrong thing well. Discovery exists to make that failure cheap, a week of interviews against a quarter of engineering is a very good trade.

In pharmaceuticals & life sciences, GxP validation means every system change needs documented evidence before it reaches production. That single fact reshapes how product design has to be built here, the guardrails, the approval points and the evidence trail are design inputs rather than things bolted on before go-live.

The workload we are most often asked to take on first is regulatory dossier assembly, usually integrated against SAP. Every engagement opens with a measurement: the cycle time, the cost per transaction, or the error rate we are being asked to move.

Built by engineers who ship production systems, not by a practice that subcontracts the build. You own the code, the models where they are open-weight, and the documentation to run it without us.

The sector constraints we design around

Defining constraint
GxP validation means every system change needs documented evidence before it reaches production
Regulations in scope
CDSCO · US FDA 21 CFR Part 11 · EU GMP Annex 11 · GxP validation · ICH guidelines
Systems of record
LIMS · QMS · eTMF · SAP · pharmacovigilance databases
Where we usually start
batch record review

Product Design workloads in pharmaceuticals & life sciences

  • batch record review
  • adverse event intake and coding
  • regulatory dossier assembly
  • deviation and CAPA drafting
  • literature monitoring

What is included

  • Problem framing before solution work. Most product failures start here
  • User and stakeholder interviews with findings you can disagree with
  • Opportunity mapping and ruthless prioritisation
  • Concept prototypes tested with real users
  • A defined first version with explicit out-of-scope
  • A roadmap that sequences by learning, not by feature list

Questions from this sector

Can an AI system be GxP validated?

Yes, with a documented validation approach, IQ/OQ/PQ, defined intended use, change control and evidence of consistent performance. We build the validation pack alongside the system, not afterwards.

How do you handle 21 CFR Part 11?

Audit trails, electronic signatures, access control and record integrity designed in from the start, because retrofitting them is effectively a rebuild.

How is this different from UI/UX design?

UI/UX designs the solution. Product design decides what the solution should be, which problem, for whom, and what the smallest version that proves it looks like.

How long does discovery take?

One to three weeks for most engagements. Longer than that and findings start going stale before anyone acts on them.

What if discovery says we should not build it?

Then it has paid for itself many times over. That outcome happens and we report it plainly.

Product Design for pharmaceuticals & life sciences, worth a conversation?

Tell us the workload and the regulation it sits under. We will tell you what is realistic.

Or email bd@dtrasglobal.com · call +91 74118 77878